iso 20916 ivd - clinical performance studies
TRANSCRIPT
![Page 1: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/1.jpg)
ISO 20916 IVD - Clinical performance studies
1
![Page 2: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/2.jpg)
2
Dr Marco Rost - Training Lead Regulatory Service (IVD)
![Page 3: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/3.jpg)
Disclaimer
3
• Information presented within this webinar is based on our current understanding of the IVDR and the standards
• Subject to change
![Page 4: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/4.jpg)
Why a webinar on a standard…
4
• IVDR has expanded stipulations for clinical performance studies
• e.g. in Article 57 to 77 andin Annex XIII, section 2
• BS ISO 20916:2019 can assist in meeting those by Good Study Practice
…in a series on IVDR?
![Page 5: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/5.jpg)
Which of the following standards do you already know?
5
a) EN 13612
b) ISO 14155
c) ISO 20916
d) All of the above
e) None of the above
![Page 6: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/6.jpg)
EN 13612
• IVD-specific• 7 clauses
Blended learning???
ISO 14155
ISO 20916
• IVD-specific • 9 clauses(common structure)
6
Context of standards
•Medical Devices(excludes IVD)
• 9 clauses(common structure)
![Page 7: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/7.jpg)
7
Specimens
representative parts taken from a specimen
SpecimenSample
Discrete portion taken from the body
Leftover
Archivedfrom repositories e.g. tissue banks
unadulterated remnantsafter all standard analysis has been performed
![Page 8: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/8.jpg)
8
Types of studies
Clinical Performance Study
Patient manage-
ment?
Specimen collection
Additional risk
Non-interventional
Interventional
Leftover/archived specimens
Body of standard+ Annex G
Body of standard+ Annex G
+ Annex A+ Annex B+ Annex C+ Annex D+ Annex E+ Annex F
No No
![Page 9: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/9.jpg)
Clinical studiesgood practice
9
5. Study planning
6. Site initiation
7. Study conduct
8. Close-out
4. Ethical considerations
9. Audit
![Page 10: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/10.jpg)
10
EthicalConsideration
• Protect rights, safety, dignity and well-being of the subjects
4.1 General
4.2 Improper influenceor inducement
• all parties involved4.3 Responsibilities
• Caveat: Local law, e.g. for medical practititioner
4.4 Ethics committeeinvolvement
• For leftover/archived specimensconsent might be in general form
4.5 Informed consent
![Page 11: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/11.jpg)
a) Yes
b) No
c) Evaluating at the moment
d) Not sure
11
Are you planning to conduct a Clinical Performance Study under the IVDR this year or next year?
![Page 12: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/12.jpg)
12
5 Study planning
12
5.1 General
5.2 Risk evaluation
5.3 Design
5.4 Investigator brochure
5.5 Clinical Performance Study Protocol (CPSP)
5.6 Case report forms
5.7 Recording of specimen information
5.8 Specimen accountability and integrity
5.9 Study site selection
5.11 Agreements
5.10 Monitoring plan
5.12 Labelling
![Page 13: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/13.jpg)
13
Need for QMS
Clinical Performance Studiesshall
5.1
Be undertaken under an effective quality
management system
e.g.
➢ ISO 13485
5.3
Use product representative of the final IVD
e.g.
➢ Process control
5.1
Have agreements with externals -
written and assumed
5.11 e.g.
➢ Investigators
➢ CRO, labs
![Page 14: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/14.jpg)
14
Some planningdocuments
• Non-annex-A studies: Instruction for Use might be okay
5.4 Investigators Brochure
• high quality, accurate and reliable data
• For annex-A-studies: plus Annex B
5.5 Clinical Performance Study Protocol (CPSP)
• Extent based on risk
• Rationale for remote monitoring5.10 Monitoring
plan
compare IVDR Annex XIII.2.3.2 Clinical Performance
Study Plan
![Page 15: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/15.jpg)
15
Annex H Good clinical performance study
documentation
• Informative
• Sets of documentationLeft-over/Archivedspecimen
Interventionalor addtitional
risk
![Page 16: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/16.jpg)
Of IVD devices5.5.3.16
• Records aboutphysical locationof all IVD
Of specimens5.7 & 5.8
• e.g. study sample log
• Ensure access todata
• E.g. for monitoring, audits, inspections
16
Accountability
![Page 17: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/17.jpg)
17
Study siteinitiation
• Initiation visit6.1 General
• Are determined6.2 Prerequisites
• Includes updates/changes
• Ensure documentation6.3 Training
• Conducting staff ready
• Pre-study documentation complete
6.4 Initiation of the study site
![Page 18: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/18.jpg)
18
Study conduct
• Start only after EC’s or authorities’ endorsement, if needed
7.1 General
• Compare Principal investigatorresponsibilities in 5.5.2 (CPSP)
7.2 Responsibilitiesof sponsor
• Focus of next slide7.3 Study site
monitoring
• Keep privacy and confidentiality
• See 4.5: de-identify specimens7.4 Data security &
confidentiality
![Page 19: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/19.jpg)
19
Monitoring•CPSP
• ISO 20916
•Ethical &
•Regulatoryrequirements
![Page 20: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/20.jpg)
Auditors• Qualified
• No direct responsibility for site or study
20
Auditing –annex I
≠• Separate from
monitoring
Audit
• Written procedures
• Specific plans
• If deficiencies, re-audit
![Page 21: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/21.jpg)
21
Adverse Event or device effect
Adverse Event
• In contextof the study
Adverse Device Effect
+ Related touse of IVD
Incident
• Differentlydefined in IVDR
IVD must be made
available
IVDR mentions abnormal laboratory
finding
![Page 22: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/22.jpg)
22
AE categorization Annex G
Adverse Event
Serious
Device-related
Anti-cipated
![Page 23: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/23.jpg)
23
Study close-out
• Complete records
• notify relevant parties8.1 Close-out
activities
• IVDR within 1 year and
• Publically available in EUDAMED
8.2 Clinical performance study report
• According to regulatory and QMS requirements
8.3 Documentretention
• Inform relevant parties
• IVDR: Study report within 3 months
8.4 Suspension orprematuretermination
![Page 24: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/24.jpg)
Summary
ISO 20916 ➢Details Good Study Practice
➢Takes into account the specifics of IVD
➢Has a modular structure
➢Helps in addressing requirements of IVDR
24
![Page 25: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/25.jpg)
www.bsigroup.com/IVDR
➢Brochures and Free Webinars…
Email:
![Page 26: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/26.jpg)
Copyright © 2020 BSI. All rights reserved
QUESTIONS?
![Page 27: ISO 20916 IVD - Clinical performance studies](https://reader030.vdocuments.net/reader030/viewer/2022012806/61bd3de161276e740b10c855/html5/thumbnails/27.jpg)
Copyright © 2020 BSI. All rights reserved
Thank you for joining today.